Your browser doesn't support javascript.
loading
Exploring the role of respiratory microbiome in lung cancer: A systematic review.
Perrone, Fabiana; Belluomini, Lorenzo; Mazzotta, Marco; Bianconi, Maristella; Di Noia, Vincenzo; Meacci, Fiammetta; Montrone, Michele; Pignataro, Daniele; Prelaj, Arsela; Rinaldi, Silvia; Russano, Marco; Sartori, Giulia; Bironzo, Paolo; Facchinetti, Francesco; Menis, Jessica; Tiseo, Marcello; Galetta, Domenico; Novello, Silvia; Pilotto, Sara.
Afiliación
  • Perrone F; Medical Oncology Unit, University Hospital of Parma, Italy. Electronic address: fabiana.perrone89@libero.it.
  • Belluomini L; Section of Oncology, Department of Medicine, University of Verona and Verona University Hospital Trust, Verona, Italy. Electronic address: lorenzo.belluomini08@gmail.com.
  • Mazzotta M; Medical Oncology Unit, Belcolle Hospital, ASL Viterbo, Viterbo, Italy. Electronic address: marcomazzotta88@gmail.com.
  • Bianconi M; U.O. Oncologia, ASUR Marche AV3, Civitanova Marche Hospital, Civitanova Marche (MC), Italy. Electronic address: stellabianconi@gmail.com.
  • Di Noia V; Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: vincedinoia@gmail.com.
  • Meacci F; Department of Oncology Radiation Therapy Unit, Careggi University Hospital, Florence, Italy. Electronic address: fiammetta.meacci1985@gmail.com.
  • Montrone M; Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy. Electronic address: m.montrone@oncologico.bari.it.
  • Pignataro D; Medical Oncology, Cardinal Massaia Hospital, Asti, Italy. Electronic address: danielepignataro89@gmail.com.
  • Prelaj A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Department of Electronics, Information, and Bioengineering, Polytechnic University of Milan, Milano, Italy. Electronic address: arsela.prelaj@istitutotumori.mi.it.
  • Rinaldi S; Medical Oncology, Augusto Murri Hospital Fermo, Fermo, Italy. Electronic address: sylvya.rinaldi85@gmail.com.
  • Russano M; Department of Medical Oncology, University Campus Bio-Medico of Rome, Rome, Italy. Electronic address: m.russano@unicampus.it.
  • Sartori G; Medical Oncology, Berica Local Health Unit, Vicenza, Italy. Electronic address: sartorigmt@gmail.com.
  • Bironzo P; Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy. Electronic address: pbironzo@gmail.com.
  • Facchinetti F; INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France. Electronic address: francescofacchinetti2@gmail.com.
  • Menis J; Section of Oncology, Department of Medicine, University of Verona and Verona University Hospital Trust, Verona, Italy. Electronic address: jessica.menis@aovr.veneto.it.
  • Tiseo M; Medical Oncology Unit, University Hospital of Parma, Italy. Electronic address: mtiseo@ao.pr.it.
  • Galetta D; Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy. Electronic address: galetta@oncologico.bari.it.
  • Novello S; Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy. Electronic address: silvia.novello@unito.it.
  • Pilotto S; Section of Oncology, Department of Medicine, University of Verona and Verona University Hospital Trust, Verona, Italy. Electronic address: sara.pilotto@univr.it.
Crit Rev Oncol Hematol ; 164: 103404, 2021 Aug.
Article en En | MEDLINE | ID: mdl-34214609
ABSTRACT
Giving the potential contribute in cancer initiation and progression, lung microbiota represents a promising topic in cancer research, although still unexplored. We performed a systematic literature search to identify clinical studies evaluating lung microbiota composition, its correlation with lung cancer patients' clinico-pathological features and prognosis. Of the identified 370 studies, 21 were eligible and included. Although studies were heterogeneous, lung cancer resulted to be enriched in peculiar microbial communities, with differences in composition and diversity according to clinico-pathological parameters. Few studies explored how lung microbiota influences cancer outcome. In light of these findings and borrowing the suggestions coming from gut microbiota, we speculate that respiratory microbiome may influence pathogenesis, progression and outcome of lung cancer. Taking advantage of the experience of chronical lung diseases, prospective studies should be designed to evaluate lung microbiota changes throughout any phase of lung cancer course, particularly with the advent of immunotherapy as pivotal treatment.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Microbiota / Microbioma Gastrointestinal / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Crit Rev Oncol Hematol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Microbiota / Microbioma Gastrointestinal / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Crit Rev Oncol Hematol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article